Eisai divests manufacturing subsidiary to Alfresa

21 December 2015
mergers-acquisitions-big

Japanese drug major Eisai (TYO: 4523) has entered into a business acquisition agreement with Alfresa Holdings, a leading local pharma wholesaler, concerning the splitting off of Eisai's consolidated pharmaceutical manufacturing and marketing subsidiary Sannova (shareholding ratio: 79.5%) via an absorption-type split, its succession by a newly established company and the subsequent transfer of all shares issued in this new company to Alfresa Holdings.

The effective date of this absorption-type split is scheduled to be March 31, 2016, and the date of the share transfer is scheduled to be April 1, 2016. Financial terms of the transaction were not revealed.

As a result of revisions in Eisai's global logistics strategy based on foreseeable adjustments to Eisai's product portfolio within a vastly changing business environment, Eisai has decided to have the business of Sannova succeeded by Alfresa Holdings. Alfresa Holdings is working to strengthen its pharmaceutical contract manufacturing business centered on its wholly-owned subsidiary Alfresa Pharma Corp, and therefore Eisai believes this business succession will lead to sustainable growth as well as further expansion of Sannova.

Eisai will continue to commission the new company that will succeed the business of Sannova via absorption-type split to manufacture Eisai products currently manufactured by Sannova, and maintain a cooperative relationship with this new company.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical